Market Research Logo

Global Ovarian Cancer Diagnostics and Therapeutics Market - Segmented by Cancer Type, Cancer Stage, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)

Global Ovarian Cancer Diagnostics and Therapeutics Market - Segmented by Cancer Type, Cancer Stage, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)

The ovarian cancer diagnostics and therapeutics market is expected to register a CAGR of 13.85% during the forecast period, 2018 to 2023. North America is expected to dominate the global market for ovarian cancer diagnostics and therapeutics due to the increasing incidence of ovarian cancer.

Increasing Population of Aged Women

The risk of ovarian cancer is higher in women in the age bracket of 55-64 years. According to the US Census Bureau, women above 60 years of age account for almost 57% of all ovarian cancer incidences and 75% of all ovarian cancer related deaths worldwide, with median age at diagnosis being 63 years and median age at death being 70 years. Thus, the increasing population of aged women is driving the growth of the ovarian cancer diagnostics and therapeutics market.

Additionally, the greater use of combination therapies for the treatment of ovarian cancer and increase in healthcare expenditure in developing countries are fueling the growth of the market.

Lack of Accurate Diagnosis of Ovarian Cancer

Accurate diagnosis for ovarian cancer is critical, as in most cases, the cancer already begins to spread to the lymph nodes and outside of the pelvis at the time of diagnosis. Ovariancancerawareness.org reports that the five-year survival rate for ovarian cancer with early stage 1 detection is 93%, and that most new cases of ovarian cancer are diagnosed at stage 3 or later, leaving little time as well as room for an accurate diagnosis. Lack of early detection and accurate diagnosis is often due to the fact that ovarian cancer symptoms are frequently overlooked, and easily confused with other conditions. Additionally, patent expiry of key drugs is also restraining the growth of the ovarian cancer diagnostics and therapeutic market.

North America to Dominate the Market

North America is dominating the market due to the increasing incidence of ovarian cancer. As per the American Cancer Society, was has been estimated that 22,280 new cases of ovarian cancer would be diagnosed in 2017, whereas in 2016, an estimated 20,000 patients were diagnosed with ovarian cancer in the United States alone.

Key Developments in the Market

  • November 2017 - Novogen Limited, an oncology-focused biotechnology company, becomes Kazia Therapeutics Limited.
  • May 2017 - A new drug developed for ovarian cancer ONX-0801 is in Phase1.
The major players include - Bristol Myers Squibb Company, Eli Lilly and Company, GlaxosmithklinePlc, Janssen Pharmaceuticals, Inc., Kazia Therapeutics Ltd, Genentech Inc., Astra Zeneca Boehringer Ingelheim, and F. Hoffman-La Roche Ltd, among others.

Reasons to Purchase the Report
  • Market analysis for the ovarian cancer diagnostics and therapeuticsmarket, with region-specific assessments and competition analysis on a global and regional scale.
  • Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
  • The treatment type that is expected to dominate the market
  • Regions that are expected to witness fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3 month analyst support, along with the Market Estimate sheet (in Excel)
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.


1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Driver
6.1.1 Increasing Incidences of Ovarian Cancer Worldwide
6.1.2 Increasing Population of Aged Women
6.1.3 Greater Use of Combination Therapies for the Treatment of Ovarian Cancer
6.1.4 Increase in Healthcare Expenditure in Developing Countries
6.2 Market Restraint
6.2.1 Patent Expiry of Key Drugs
6.2.2 Lack of Accurate Diagnosis of Ovarian Cancer
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Cancer Type
7.1.1 Epithelial Ovarian Tumors
7.1.2 Ovarian Germ Cell Tumors
7.1.3 Ovarian Stromal Tumors
7.1.4 Primary Peritoneal Carcinoma
7.2 By Cancer Stage
7.2.1 Stage I
7.2.2 Stage II
7.2.3 Stage III
7.3 By Diagnosis
7.3.1 Physical Examination
7.3.2 Biopsy
7.3.3 Blood Tests
7.3.4 Human Chorionic Gonadotropin (HCG) Test
7.3.5 Ultrasound
7.3.6 PET
7.3.7 CT Scan
7.3.8 Others
7.4 By Treatment
7.4.1 Chemotherapy
7.4.1.1 Paclitaxel
7.4.1.2 Docetaxel
7.4.1.3 Cisplatin
7.4.1.4 Carboplatin
7.4.1.5 Others
7.4.2 Targeted Therapy
7.4.2.1 Bevacizumab
7.4.2.2 Olaparib
7.4.3 Radiation Therapy
7.4.4 Immunotherapy
7.4.4.1 Carboplatin
7.4.4.2 Paclitaxel
7.4.5 Hormonal Therapy
7.4.5.1 Goserelin
7.4.5.2 Leuprolide
7.5 By Geography
7.5.1 North America
7.5.1.1 US
7.5.1.2 Canada
7.5.1.3 Mexico
7.5.2 Europe
7.5.2.1 France
7.5.2.2 Germany
7.5.2.3 UK
7.5.2.4 Italy
7.5.2.5 Spain
7.5.2.6 Rest of Europe
7.5.3 Asia-Pacific
7.5.3.1 China
7.5.3.2 Japan
7.5.3.3 India
7.5.3.4 Australia & New Zealand
7.5.3.5 South Korea
7.5.3.6 Rest of Asia-Pacific
7.5.4 Middle East & Africa
7.5.4.1 GCC
7.5.4.2 South Africa
7.5.4.3 Rest of Middle East & Africa
7.5.5 South America
7.5.5.1 Brazil
7.5.5.2 Argentina
7.5.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Astra Zeneca
9.2 Boehringer Ingelheim
9.3 Bristol Myers Squibb Company
9.4 Eli Lilly and Company
9.5 F. Hoffman-La Roche Ltd
9.6 Genentech Inc.
9.7 Glaxosmithkline Plc
9.8 Janssen Pharmaceuticals, Inc.
9.9 Kazia Therapeutics Ltd
*List Not Exhausitive
10. Outlook of the Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report